ライフサイエンスコーパス: intradermal

1 intradermal 2.22 [1.83-2.69], and 1/27 dose intradermal 1.64 [1.35-2.00]).

2 dose intradermal 2.58 (2.13-3.13), 1/10 dose intradermal 2.22 [1.83-2.69], and 1/27 dose intradermal

3 neous GMFR 1.64 [90% CI 1.36-1.99], 1/3 dose intradermal 2.58 (2.13-3.13), 1/10 dose intradermal 2.22

4 d that scratching behavior, evoked by direct intradermal activation of TRPV4, was critically dependen

5 L HelmJect auto-disable syringe with a Helms intradermal adapter).

6 Novel intradermal devices, including intradermal adapters and disposable-syringe jet injector

7 bility in response to VEGF, administered via intradermal adenoviral delivery or through systemic inje

8 nfused VEGF, ii) ear angiogenic responses to intradermal adenoviral-VEGF injection, and iii) vascular

9 Intradermal adipose tissue plays an essential role for h

10 onments that communicate with the follicles: intradermal adipose tissue, innate immune system, sex ho

11 These data support that this simple intradermal-administered, serology-independent approach

12 ent dose-response relation was observed with intradermal administration (1/3 dose subcutaneous GMFR 1

13 ythema and induration were more common after intradermal administration (31% erythema for full subcut

14 f a simple, more tolerable, and dose-sparing intradermal administration followed by electroporation g

15 Intradermal administration had higher a incidence of loc

16 (CD44), the cognate hyaluronan receptor, and intradermal administration of A5G27, a CD44 receptor ant

17 Intradermal administration of BoNT-A to healthy voluntee

18 Intradermal administration of fractional inactivated pol

19 Larger and longer studies of intradermal administration of live, attenuated zoster va

20 a minimally invasive delivery system for the intradermal administration of nucleic acids, both plasmi

21 ointestinal symptoms that followed the first intradermal administration of the vaccine resembled thos

22 antibodies to MVA were only detectable after intradermal administration of the vaccine.

23 We aimed to determine whether intradermal administration of zoster vaccine could enhan

24 MTD of Nexvax2 was 150 mug for twice weekly intradermal administration over 8 weeks, which modified

25 4) at 6 weeks post-vaccination compared with intradermal administration which resulted in a significa

26 lumes that are considered to be standard for intradermal administration, and postulate a hydrodynamic

27 controlled transdermal delivery and targeted intradermal administration.

28 ction in antibody titers is possible through intradermal administration.

29 formulation, or placebo, by subcutaneous or intradermal administration.

30 ENvax, or placebo, by either subcutaneous or intradermal administration.

31 A limitation of the study is that while the intradermal-aerosol regimen induced the most potent cell

32 Only the intradermal-aerosol vaccination regimen (Group 2) result

33 gous (Group 1, aerosol-intradermal; Group 2, intradermal-aerosol) or homologous (Group 3, intradermal

34 Hence, it appears that the combination of intradermal Ag administration and draining LN sampling c

35 Skin biopsy specimens were collected after intradermal allergen challenges, and late-phase response

36 Intradermal allergen immunotherapy suppressed skin late-

37 Repeated low-dose grass pollen intradermal allergen injection suppresses allergen-induc

38 sters formed on top of LPRs induced by using intradermal allergen injection were assessed for HLA-DR(

39 Cutaneous response was measured by intradermal allergen injection.

40 d allergic rhinitis to receive 7 preseasonal intradermal allergen injections (containing 7 ng of Phl

41 oncept constitutes important progress in the intradermal analysis of ions related to an electrolyte i

42 on and (2) between AD participants receiving intradermal and intramuscular vaccination.

43 jet injector was assessed by comparison with intradermal and subcutaneous injection of antigen using

44 Nanoparticle-based intradermal antigen delivery may therefore provide a new

45 For risk assessment, safe intradermal application of these pigments needs data for

46 immunization and achieve high coverage with intradermal application.

47 The intradermal arm tested daily intradermal injection of ge

48 Participants were challenged with intradermal BCG 4 weeks after those who received MVA85A.

49 thin the confines of the bleb created by the intradermal bolus.

50 In this trial, the aerosol prime-intradermal boost regime was well tolerated, but intrade

51 ompared with noncolonized participants after intradermal but not intramuscular vaccination.

52 ic influenza vaccines after a single dose of intradermal, but not intramuscular, immunization.

53 After intradermal, but not intramuscular, vaccination, partici

54 on 16 cows that were positive by the single intradermal cervical comparative tuberculin (SICCT) test

55 ng in a potency of 79.4 IU/mg in the in vivo intradermal challenge assay.

56 Employing an intradermal challenge model in mice, we report that cuta

57 lls in the blood, and showed protection from intradermal challenge with melanoma cells.

58 cell infiltrations in the lesions 48 h after intradermal challenge.

59 anglion pruriceptors, and (iii) injection of intradermal citric acid (pH 3.0) into the nape induced a

60 rom 7 governorates were tested by the Single Intradermal Comparative Skin Tuberculin (SICST), as a pr

61 uld permit the translation of laser-assisted intradermal delivery of a tumor-specific vaccine targeti

62 suitable drug delivery system to facilitate intradermal delivery of autoantigens in a minimally inva

63 The results suggest that intradermal delivery of IPV may lead to dose-sparing eff

64 In the recent past, the intradermal delivery of NPs, via novel dissolving micron

65 Intradermal delivery of partial vaccine doses induced an

66 the use of the hollow microneedle array for intradermal delivery of polymeric nanoparticles (NPs) in

67 esults show that hollow microneedle mediated intradermal delivery of polymeric NPs is a promising app

68 s and subcutaneous routes of administration, intradermal delivery of polymeric NPs via a hollow micro

69 Intradermal delivery of vaccines has been shown to resul

70 ive treatment for HS by establishing a novel intradermal delivery system with a dissolving microneedl

71 f the three drugs in rat, achieved following intradermal delivery, ranged between 4- and 7-fold highe

72 decreased anti-vector responses, compared to intradermal delivery.

73 Ex vivo tests based on the intradermal detection of potassium in chicken and porcin

74 Novel intradermal devices, including intradermal adapters and

75 and C57BL/6 mice in vitro and in vivo after intradermal DNA vaccination.

76 given as a full intramuscular or fractional intradermal dose by needle and syringe or disposable-syr

77 ticipants boosted with an 80 mug needle-free intradermal dose of CV7201 achieved titres of 0.5 IU/mL

78 thema for full subcutaneous dose and 77% for intradermal dose).

79 vaccine given subcutaneously or one of four intradermal doses (full, 1/3, 1/10, or 1/27 dose) using

80 The administration of single fractional intradermal doses of IPV by needle and syringe or dispos

81 the antibody titres generated by fractional intradermal doses of IPV did not achieve non-inferiority

82 nogenicity of fractional (one-fifth, 0.1 mL) intradermal doses of the inactivated poliovirus vaccine

83 The two subcutaneous doses and the four intradermal doses were randomised (1.5:1:1:1:1:1) by com

84 - microparticles for targeted and sustained intradermal drug delivery.

85 red to wild-type mice after Leishmania major intradermal ear infection.

86 iple studies have assessed immunogenicity of intradermal fIPV compared with the full intramuscular do

87 s positively correlated with the size of the intradermal fluid bleb.

88 . falciparum rPfHRP2 and total IgG) from the intradermal fluid of live mice in situ, for subsequent d

89 outer skin layers to interface directly with intradermal fluid.

90 Using a model of intradermal footpad injection of Candida albicans, we ob

91 (CVC) and sweat rate were evaluated at four intradermal forearm skin sites: (i) control; (ii) 10 mm

92 ted poliovirus vaccine (IPV) with 2 doses of intradermal fractional-dose IPV (fIPV) in its routine im

93 Both topical and intradermal gentamicin administration induced type VII c

94 Herein, we determined whether topical or intradermal gentamicin administration induces type VII c

95 assessed safety and efficacy of topical and intradermal gentamicin in 5 RDEB patients with nonsense

96 Topical and intradermal gentamicin suppresses nonsense mutations and

97 were higher in the aerosol group than in the intradermal group.

98 using either heterologous (Group 1, aerosol-intradermal; Group 2, intradermal-aerosol) or homologous

99 Following intradermal hybrid tracer administration, lymphoscintigr

100 nicity, but there are few safe and effective intradermal (i.d.) adjuvants.

101 Dorsal intradermal (i.d.) administration of AYP elicited intens

102 Here we evaluated single versus concurrent intradermal (i.d.) and intramuscular (i.m.) vaccinations

103 ved survival from intraperitoneal (i.p.) and intradermal (i.d.) challenge by L. interrogans serovar C

104 or, which is transmitted in nature following intradermal (i.d.) deposition of parasites by the bite o

105 Intradermal (i.d.) immunization of mice with recombinant

106 In A. nancymaae, intradermal (i.d.) immunization with chimera plus single

107 IVM of popliteal LNs after intradermal (i.d.) injection of bacteria in the footpad

108 nd on a previous report where we implemented intradermal (i.d.) inoculations to study bacterial disse

109 Here, we investigated the intradermal (i.d.) or sublingual (s.l.) delivery of CFA/

110 esponse quality after transcutaneous (t.c.), intradermal (i.d.), and intramuscular (i.m.) administrat

111 The World Health Organization recommends intradermal (ID) administration of rabies vaccine for pr

112 Compared to conventional "wet" intradermal (ID) administration, "dry" peptide delivered

113 f different tissues via transcutaneous (TC), intradermal (ID) and intramuscular (IM) injection has th

114 We developed an intradermal (ID) challenge cynomolgus macaque (Macaca fa

115 Intradermal (ID) delivery of influenza vaccine might imp

116 ed a primary vaccination that consisted of 2 intradermal (ID) doses of 0.1 mL of the purified chicken

117 Intradermal (id) fractional inactivated poliovirus vacci

118 Intradermal (ID) immunization is an attractive route of

119 -OVA antibody titer at a level comparable to intradermal (ID) injection and was much more efficient t

120 able, safe and efficient means to administer intradermal (ID) injections.

121 Seven days later, mice received intradermal (id) microinjection of histamine, chloroquin

122 travenous (IV) administration of RAS, not by intradermal (ID) or subcutaneous (SC) vaccination.

123 d immunogenicity of a 2-visit (days 0 and 7) intradermal (ID) primary vaccination (2 doses of 0.1 mL

124 Interstitial, e.g. subcutaneous (SC) or intradermal (ID), administration of monoclonal antibodie

125 as in a mouse model of psoriasis induced by intradermal IL-23 injections and in IL-17A-treated kerat

126 prominent in galectin-8-knockout mice after intradermal IL-23 treatment than in wild-type mice.

127 Furthermore, intradermal immunization of BALB/c mice indicated that h

128 Intradermal immunization of mice against hepatitis B sur

129 V was studied by comparing intramuscular and intradermal immunization of Wistar rats using NanoPass M

130 Moreover, a single intradermal immunization protected mice against melanoma

131 ficacy of BCG-MNAs was comparable to that of intradermal immunization whether it was evaluated by hum

132 r helper and germinal center formation after intradermal immunization with HIV p24-coated polylactic

133 Here we demonstrate that a single low-dose intradermal immunization with lipid-nanoparticle-encapsu

134 To address this issue, we used intradermal immunization with plasmid DNA, a system in w

135 outcomes when compared with 12 conventional intradermal immunotherapies.

136 from biopsy specimens of subjects undergoing intradermal immunotherapy had higher expression of the T

137 uate the efficacy and safety of grass pollen intradermal immunotherapy in the treatment of allergic r

138 Intradermal immunotherapy increased serum Phleum pratens

139 In a per-protocol analysis intradermal immunotherapy was further associated with wo

140 vitro treatment of MyD88(-/-) APCs with and intradermal in vivo injections of PARP inhibitor, PJ-34,

141 ding (i) subcutaneous infection models, (ii) intradermal infection models, (iii) wound infection mode

142 Intradermal infection of mice with a virus lacking A55R

143 ural route of infection with VACV is through intradermal infection of the skin.

144 ed the role of ROS in C57BL/6 mice following intradermal infection with Leishmania amazonensis.

145 to limit host-protective immunity following intradermal infection with Trypanosoma cruzi.

146 zed by reduced lethality following high-dose intradermal infection, an altered cytokine response in t

147 erial distribution in tissues differed after intradermal infection, compared with the distribution af

148 murine models of both skin colonization and intradermal infection.

149 and induction of adaptive immunity following intradermal infection.

150 r MyD88 in protective immunity to VACV after intradermal infection.

151 local control of virus replication following intradermal infection.

152 Intradermal infections had higher var gene transcript le

153 eutrophilic inflammation in a human model of intradermal inflammation.

154 Although we have shown that a standard-dose intradermal influenza vaccine versus a standard-dose int

155 In contrast, intradermal infusion of HYPER saline did not affect swea

156 Intradermal infusion of HYPER saline increased baseline

157 Furthermore, we examined if local intradermal infusion of hyperosmotic saline affects swea

158 In contrast, local intradermal infusion of hyperosmotic saline did not affe

159 early mechanisms occurring in the skin after intradermal injection and EP of the auxoGTUmultiSIV DNA

160 ptake of fluorescently labeled albumin after intradermal injection by LECs was similar to that of der

161 observed for the group receiving one 6-nmol intradermal injection every 2 weeks for 14 weeks at GPS3

162 s observed in the group receiving one 6-nmol intradermal injection every 2 weeks for 14 weeks group c

163 Upon intradermal injection in the hindleg, a fraction of both

164 pment of psoriasiform dermatitis in an IL-23 intradermal injection model.

165 Intradermal injection of acid generates pain in both rod

166 Furthermore, intradermal injection of ADSCs along with BA-DEG-BA into

167 Angiogenesis induced by tumors arising from intradermal injection of B16 F1 melanoma cells was also

168 rin (BCG) and subsequent activation using an intradermal injection of BCG in complete Freund adjuvant

169 Superficially applied capsaicin and intradermal injection of beta-alanine, an MrgprD agonist

170 In this study, we demonstrate that intradermal injection of CaP into mice triggered scratch

171 The intradermal arm tested daily intradermal injection of gentamicin solution (8 mg) or p

172 local abrogation of IkappaBzeta function by intradermal injection of IkappaBzeta siRNA abolished pso

173 Finally, intradermal injection of IL-17A in standard diet-fed mic

174 Intradermal injection of IL-23 bypassed the requirement

175 L-23 pathway is activated, a murine model of intradermal injection of IL-23 was used.

176 subjected to the identical CHMI protocol by intradermal injection of P. falciparum sporozoites.

177 the skin and surrounding hair follicles via intradermal injection of recombinant R-spondin2 protein.

178 is when administered 2 days after orthotopic intradermal injection of the cells, or when treatment st

179 TRPM3-expressing somatosensory neurons, and intradermal injection of the compound induced a TRPM3-de

180 Subcutaneous, intramuscular and intradermal injection of the LNP-encapsulated mRNA trans

181 Repeated intradermal injection of the selective mu-opioid recepto

182 protection from lethal disease is induced by intradermal injection of vaccinia virus, whereas a prote

183 extended presentation of antigen in skin via intradermal injection or microneedle patch can enhance i

184 mug keyhole limpet haemocyanin) via monthly intradermal injection until progression or intolerance,

185 mmunization site following intramuscular and intradermal injection using optimized synthetic DNA vacc

186 Mice vaccinated by intradermal injection using the jet injector or subcutan

187 We used a model of intradermal injection with fluorescent-labeled, nonviabl

188 skin architecture and, unlike a conventional intradermal injection, MicronJet administration of a 50m

189 ere applied to MC-deficient mice by means of intradermal injection.

190 ining lymph nodes compared to a conventional intradermal injection.

191 intradermal injections caused ~3 nm shift.

192 ed and/or expressed the mRNA over 72 h after intradermal injections into primary, human, skin explant

193 y randomly generated sequence to receive two intradermal injections of either MVA85A or placebo.

194 Some mice were given intradermal injections of gliadin in complete Freund's a

195 Furthermore, intradermal injections of HP-NAP-encoding adenovirus in

196 By administering daily intradermal injections of inactivated polio vaccine acco

197 Of clinical relevance, intradermal injections of ML204 in psoriasiform skin sig

198 ith type 2 diabetes mellitus (T2DM) received intradermal injections of modified mRNA encoding vascula

199 del, we studied skin inflammation induced by intradermal injections of preactivated IL-36alpha.

200 silencing TRPC4 in DRG and its inhibition by intradermal injections were also effective in decreasing

201 trast to the overt skin irritation caused by intradermal injections.

202 Intradermal inoculation of DENV protease packaged in ade

203 rol Leishmania major infection in vitro, and intradermal inoculation of Leishmania resulted in a more

204 also support human skin infection following intradermal inoculation with community-associated methic

205 Intradermal inoculation with the F. tularensis live vacc

206 ess invasive routes, such as subcutaneous or intradermal inoculations are rare, even though the shari

207 intradermal-aerosol) or homologous (Group 3, intradermal-intradermal) immunisation.

208 One fractional dose of intradermal IPV gave lower seroconversion (10%-40%), but

209 Intradermal IPV shows promise as a means to decrease the

210 Importantly, painless intradermal jet delivery of DNA was as effective as deli

211 Differences in titer observed between intradermal jet injected and needle injected animals ref

212 er presents results from an ex-vivo study of intradermal jet injections, which is an attractive metho

213 Thus, intradermal JT010 injection can serve as a tool to valid

214 y transduced autologous epidermal grafts and intradermal lentivirally engineered fibroblast injection

215 ultiple-patterned spiking was not induced by intradermal lidocaine, was independent of stimulus modal

216 cycles of combination chemotherapy, then an intradermal lower abdominal injection of granulocyte-mac

217 Ex vivo intradermal microdialysis combined with culture media an

218 with laser Doppler flowmetry during low dose intradermal microdialysis ET-1 perfusions (1, 3, 4, 5 an

219 In Protocol 2, an intradermal microdialysis fibre was placed in the skin o

220 te day, subjects were instrumented with four intradermal microdialysis fibres on the forearm and each

221 oppler flowmetry) was measured during graded intradermal microdialysis perfusion of the endothelium-d

222 vascular conductance were measured over two intradermal microdialysis probes, one perfused with ISO

223 Intradermal microdialysis was utilized for up to 24h aft

224 forearm skin sites continuously perfused via intradermal microdialysis with: (1) lactated Ringer solu

225 tivity were assessed pharmacologically using intradermal microdialysis.

226 tudy aims to develop, for the first time, an intradermal MN delivery system to target proinsulin, a l

227 rimental low-dose (300 colony-forming units) intradermal model of infection in rabbits, which reprodu

228 and decreased immune cell infiltration in an intradermal model of infection yet still elicited protec

229 ogenic than wild-type VACV in intranasal and intradermal models of infection.

230 Using a murine model of intradermal MRSA infection, the therapeutic efficacy of

231 sol MVA85A and intradermal saline placebo or intradermal MVA85A and aerosol saline placebo.

232 Boosting an intradermal MVA85A prime with an aerosolised MVA85A boos

233 Intradermal MVA85A was associated with expected mild loc

234 Intradermal MVA85A, a candidate vaccine against tubercul

235 ved that mice were best protected against an intradermal needle challenge with Leishmania major and s

236 Ex vivo intradermal neonatal porcine skin penetration of VD3 NMP

237 ng misclassified, with the most common being intradermal nevi.

238 Common classification errors included intradermal nevus misclassified as basal cell carcinoma

239 Compared with intradermal or aerosol delivery, intravenous immunizatio

240 mRNA vaccination by needle-free intradermal or intramuscular device injection induced vi

241 Conversely, intradermal or intramuscular needle-syringe injection wa

242 sessed for eligibility, 347 of whom received intradermal or intramuscular vaccination per label and w

243 malaria-naive individuals were inoculated by intradermal or intravenous injection with cryopreserved,

244 Superficial (intradermal or periareolar) or deep (peritumoral or intr

245 mmediate clinical hypersensitivity following intradermal OVA challenge.

246 as the built-in engine for deeper and faster intradermal payload delivery.

247 new analytical all-solid-state platform for intradermal potentiometric detection of potassium in int

248 adermal boost regime was well tolerated, but intradermal prime-aerosol boost resulted in transient bu

249 ing with aerosol-inhaled MVA85A enhanced the intradermal primed responses in Group 2.

250 Intradermal priming of engrafted NSG-SGM3 mice with a ch

251 tologic examination showed heavily pigmented intradermal proliferation of large, epithelioid melanocy

252 y be involved in the scratching responses to intradermal pruritogens, this is unlikely to be due to a

253 loroquine can impair the immune responses to intradermal rabies vaccination.

254 the administration of sequential doses of an intradermal rabies vaccine was shown to result in reduce

255 EMLA by the intravenous, intraperitoneal, or intradermal route and evaluated for clinical and patholo

256 oliovirus vaccine (fIPV) administered by the intradermal route delivers one fifth of the full vaccine

257 inase (PEPCK) by EP and again found that the intradermal route was superior to the intramuscular rout

258 ur-fold rise in titres was also lower by the intradermal route.

259 tical for Schu S4 virulence, but only by the intradermal route.

260 virulence in mice by both the intranasal and intradermal routes of infection.

261 of TDV 90 days apart via the subcutaneous or intradermal routes.

262 By contrast, an intradermal S. aureus challenge promoted MyD88-dependent

263 is study, we examined the effects induced by intradermal S. aureus LTA.

264 nvelopes into two groups: aerosol MVA85A and intradermal saline placebo or intradermal MVA85A and aer

265 , pegylated IFN-alpha2b , or ribavirin using intradermal, scratch, and/or patch tests, as well as lym

266 x trials), sublingual (four trials), oral or intradermal SIT in children/adults allergic to house dus

267 "de-labeling," "prick or epicutaneous," and "intradermal" skin testing, "oral challenge or provocatio

268 hy BCG-naive adults were assigned to receive intradermal standard-dose BCG SSI (group A), standard-do

269 This results in intradermal tattooing of the topical product.

270 Lab ApS, Denmark), skin prick test (SPT) and intradermal test (IDT).

271 tem examination was performed on comparative intradermal test-positive cattle that died.

272 For intradermal testing and allergen immunotherapy, a good k

273 In vivo allergenic potency was determined by intradermal testing of 51 Japanese adults with positive

274 s based on sensitization rates identified by intradermal testing or serum testing for allergen-specif

275 hylaxis was confirmed in six cases: positive intradermal tests (n = 4), a syndromic reaction during s

276 pha-associated exanthemas displayed positive intradermal tests to PEG-IFNs but not to conventional IF

277 Skin prick and intradermal tests with cetuximab were clearly positive i

278 end points, nasal symptoms were worse in the intradermal treatment group, as measured based on daily

279 sh-colored melanocytic BAP1-mutated atypical intradermal tumors (MBAITs).

280 These responses suppress the growth of intradermal tumors and disseminated melanoma lacking the

281 with AD and nonatopic participants receiving intradermal vaccination and (2) between AD participants

282 s study was to compare antibody responses to intradermal vaccination in participants with moderate/se

283 to evaluate whether alternating aerosol and intradermal vaccination routes would boost cellular immu

284 overt skin irritation, in marked contrast to intradermal vaccination that provoked severe inflammatio

285 Intradermal vaccination was done using the NanoPass Micr

286 ild local injection site reactions following intradermal vaccination.

287 l CD4+ and CD8+ T cell cytokines compared to intradermal vaccination.

288 ies to Ag85A and MVA were only induced after intradermal vaccination.

289 ed (3:2) to receive sunitinib plus up to ten intradermal vaccinations of IMA901 (4.13 mg) and granulo

290 ced transdermal drug delivery and "targeted" intradermal vaccine administration.

291 We evaluated an intradermal vaccine using HIV-1 p24 Gag peptide-conjugat

292 Intradermal VEGF-A mRNA was well tolerated and led to lo

293 the extent of erythema and induration after intradermal VZV antigen injection.

294 V) vectors for gene delivery to the TG after intradermal whiskerpad delivery in mice.

295 ene delivery to TG sensory neurons following intradermal whiskerpad injection.

296 Intradermal zoster vaccine showed a greater increase in

297 l zoster vaccine, 35 to receive the 1/3 dose intradermal zoster vaccine, 34 to receive the 1/10 dose

298 zoster vaccine, 34 to receive the full dose intradermal zoster vaccine, 35 to receive the 1/3 dose i

299 zoster vaccine, 34 to receive the 1/10 dose intradermal zoster vaccine, and 34 to receive the 1/27 d

300 ter vaccine, and 34 to receive the 1/27 dose intradermal zoster vaccine.